1. Recommendations to address key recruitment challenges of Alzheimers disease clinical trials.
- Author
-
Langbaum, Jessica, Zissimopoulos, Julie, Au, Rhoda, Bose, Niranjan, Edgar, Chris, Ehrenberg, Evan, Fillit, Howard, Hill, Carl, Hughes, Lynne, Irizarry, Michael, Kremen, Sarah, Lakdawalla, Darius, Lynn, Nancy, Malzbender, Kristina, Maruyama, Tetsuyuki, Massett, Holly, Patel, Deep, Peneva, Desi, Reiman, Eric, Romero, Klaus, Routledge, Carol, Weninger, Stacie, Aisen, Paul, and Weiner, Michael
- Subjects
Alzheimers disease ,clinical trials ,diversity in clinical trials ,recruitment ,retention ,trial participation ,Humans ,Alzheimer Disease ,Patient Selection - Abstract
Clinical trials for Alzheimers disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient-advocacy organizations, philanthropy, non-profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimers clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panels recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD.
- Published
- 2023